It could take years before Novo Nordisk has fulfilled demand for weight loss drugs, the company’s chief executive told CNN, noting there are more than 100 million Americans with obesity and that “many of those would like to be on treatment.”
It could take years before Novo Nordisk has fulfilled demand for its highly popular weight loss drug, the company’s chief executive told CNN, noting that there are more than 100 million Americans with obesity and that “many of those would like to be on treatment.” The Danish drugmaker has limited starter doses of Wegovy, which was approved in the US in 2021 for chronic weight management, as it struggles to meet demand, and CEO Lars Fruergaard Jorgensen said it’s not clear when that will stop.
“In Denmark, we have 1% of the population on Wegovy.” It’s just now starting to become available in Germany and the UK as well. Paying for the drug can be another challenge, if patients are able to start treatment. It costs $1,350 a month in the US before insurance, and coverage can be spotty, doctors have told CNN. And studies of Wegovy and other similar drugs in the class, known as GLP-1 receptor agonists, suggest that people must keep taking them to maintain weight loss.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk launches weight-loss drug Wegovy in UKNovo Nordisk launched its weight-loss injection Wegovy in Britain on Monday, its second debut in Europe in just over a month as the drugmaker seeks to expand in the region even as it struggles to keep up with soaring demand.
Read more »
Weight-Loss Drug Wegovy Launches In U.K. As Shares Of Drugmaker Novo Nordisk Hit New PeakIn August, Novo Nordisk's CEO said it could “take quite some years” for the company to meet soaring demand for the popular drug.
Read more »
Novo Nordisk's Wegovy weight loss drug launches in the UKNovo Nordisk launched its Wegovy weight loss injection in the U.K. Monday, furthering the drug’s rollout in Europe despite ongoing supply constraints.
Read more »
Wegovy makes UK weight-loss debut even as Novo struggles with supplies By ReutersWegovy makes UK weight-loss debut even as Novo struggles with supplies
Read more »
Novo Nordisk Is Now Europe’s Biggest Company, Driven by Weight-Loss Drug. How Eli Lilly Could Benefit.The pharma company's Wegovy medication helps it overtake luxury goods maker LVMH, with a market value of around $420 billion.
Read more »
Gala Games CEO sues co-founder alleging $130 million theft, pattern of deceptionThe co-founder filed his own lawsuit in response, alleging the CEO used the company to enrich himself, including a corporate jet.
Read more »